Author + information
- Smit Patel,
- Uvesh Mansuri,
- Rupak Desai,
- Neel Patel,
- Mohit Pahuja,
- Ronak Soni,
- Chankrit Sethi,
- Purav Patel and
- Vinshi Naz Khan
Background: Atrial fibrillation (AFib) accounts for high rates of unfavorable outcomes in cardiac as well as non-cardiac patients. The unplanned 30-day readmission rate, cost burden and predictors in AFib patients treated with or without Endovascular Ablation (EVA) remain unclear.
Methods: We used National readmission dataset (NRD 2013) to estimate 30-day readmission for AFib patients from January to December 2013 excluding the elective readmission. The AFib and EVA were identified by using ICD-9 code 427.31 and 37.34 respectively. Logistic Regression analysis was used to identify independent predictors of unplanned 30-day readmission after adjusting for the stratified cluster design of NRD. The cost of readmission was calculated by multiplying total charges with the cost to charge ratio provided by healthcare cost and utilization project (HCUP).
Results: The NRD contained 165,572 (weighted N = 382,303) AFib patients without EVA and 11,228 (weighted N = 24,492) AFib patients with EVA. The all-cause readmission rate was 10.8% vs. 13.7% for EVA treated AFib patients. The multivariate analysis for readmission of without EVA vs. with EVA treated AFib patients are shown in table 1. The total readmission cost was approximately $5.07 million vs. $602 million in EVA treated AFib patients.
Conclusions: EVA is emphatically identified with lower 30-day readmission in AFib patients. Reducing 30-day unplanned readmission rates will lower the financial weight on the social insurance framework in the US.
Poster Hall, Hall C
Friday, March 17, 2017, 3:45 p.m.-4:30 p.m.
Session Title: Arrhythmias and Clinical EP: Basic 2
Abstract Category: 4. Arrhythmias and Clinical EP: Basic
Presentation Number: 1152-116
- 2017 American College of Cardiology Foundation